In COVID-19 BALB/c mouse models established by using the CoV-MHV-A59 virus, researchers found that thymosin drugs could balance the host immune response, and attenuate virus-induced inflammatory pathologic injury by inhibiting virus replication, and reducing the level of CRP and inflammatory mediators, thus promoting organ repair and increasing the survival rate of the mice infected with the MHV-A59 virus. Here, CRP is linked to COVID-19.